Company intelligence / Profile preview

Peptomyc

Ownership: Private
Employees: ~15
Development stage: Phase 2

Overview

Peptomyc’s lead candidate, OMO103, a first-in-class MYC inhibitor based on the Omomyc mini-protein, has demonstrated safety and clinical activity in a completed Phase I trial for solid tumors. Results were published in Nature Medicine in February 2024. The company has initiated a Phase Ib trial in pancreatic cancer and continues to develop additional pipeline programs.

Therapeutic areas: Oncology
Modalities: Cell penetrating peptides (CPPs)Mini-proteins/Protein therapeutics
Industry: Biotech

Drug pipeline

1 asset

OMO-103

Partnerships

EIT Health support/programs

Beyond the preview

Go deeper on Peptomyc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptomyc.

Explore the full profile